Ngwaahịa

Nkọwa:
prim-o-glucosylcimifugin nwere mmetụta mgbochi mkpali dị ike.Enwere ike igbochi okwu iNOS na COX-2 site na ịhazi transd mgbaàmà JAK2 / STAT3.

Otu dị mkpa:
Ụzọ mgbaama > > mgbochi na mbufụt > > nitric oxide synthase
Ogige nyocha > > mbufụt / mgbochi
Ngwaahịa eke > > ndị ọzọ

Ebumnuche:iNOS
COX-2

N'ime Vitro Ọmụmụ:
prim-o-glucosylglycine (POG) bụ ọdịnaya kachasị elu nke chromone yana otu n'ime ihe ndị na-arụ ọrụ na Fangfeng (RS).Prim-o-glucosylglycine na-arụ ọrụ mgbochi mkpali na raw 264.7 macrophages site na igbochi ntụgharị akara JAK2 / STAT3 na igbochi okwu nke iNOS na COX-2.A tụrụ cytotoxicity nke prim-o-glucoside na LPS na-arụ ọrụ macrophages raw 264.7.Jiri LPS (1 μ G / ml) na ịba ụba nke prim-o-glucosylglycine (15, 50 na 100 μ G / ml) maka awa 24, na nyocha CCK-8 na-enyocha ike cell.E jiri ya tụnyere mkpụrụ ndụ DMSO a na-emeso (njikwa), awa 24 na ikpughe na 15-100 μ Mgbe g / ml prim-o-glucoside gasịrị, emetụtaghị ike ndụ cell.Iji mụọ mmetụta mgbochi mkpali nke prim-o-glucosylglycine, ma prim-o-glucosylglycine nwere ike imetụta NO synthesis e nyochara na LPS activated raw 264.7 sel.Jiri LPS (1 μ G / ml) na ọkwa dị iche iche nke prim-o-glucosylglycine (15, 50 na 100 μG / ml) maka awa 24.Ejighi mmeghachi omume Griess tụọ ntinye uche n'ọdịnala.Nleba nke mba dị na omenala abawanyela nke ukwuu site na mkpughe LPS, na prim-o-glucoside gbochiri LPS ebuteghị mmepụta n'ụzọ dabere na ntinye uche [1].
Na Ọmụmụ Vivo
A na-anakọta mmiri mmiri bronchoalveolar lavage (BALF) 7 awa mgbe nchịkwa lipopolysaccharide (LPS), na ọkwa cytokine dị na BALF bụ ELISA tụrụ.E jiri ya tụnyere otu njikwa, TNF na BALF- α, IL-1 β Na ọkwa IL-6 mụbara nke ukwuu.Otú ọ dị, tupu ọgwụgwọ ya na prime-o-glucosylglycine (2.5, 5 ma ọ bụ 10 mg / kg) na-agbadata nke ọma TNF-α, IL-1 β na IL-6 n'ụzọ dabere na dose (P <0.05, P <0.05, 0.01). ) [1].

Nnwale cell
A na-eji ngwa ọnụ ọgụgụ cell (CCK-8) chọpụta mkpokọta cytotoxic nke prim-o-glucosylglycine.Na nkenke, a na-agwọ mkpụrụ ndụ 264.7 raw 1 kwa olulu mmiri × Njupụta nke sel 104 ka etinyere na olulu mmiri 96 ma tinye ya n'otu abalị.Mgbe ahụ jiri 1 μ Cell kpalitere g / ml LPS wee mesoo ya na ọkwa dị iche iche nke prim-o-glucosylglycine (15, 50 na 100 μ g / ml; Medchem express, Princeton, NJ, USA) ma ọ bụ ọgwụgwọ DMSO.Mgbe incubation na 37 ℃ maka awa 24, a na-agbakwunye CCK-8 ngwọta na nke ọ bụla ma tinye ya maka awa ọzọ.A tụrụ absorbance na 450 nm site na iji onye na-agụ microplate [1].

Nnwale anụmanụ
oke [1] BALB/C ụmụ oke nwoke, dị izu asatọ, na-eru ihe dịka 18 ruo 20g.E kewara ụmụ oke na-enweghị usoro na otu 5: otu njikwa;otu LPS;LPS + prime-o-glucosylglycine (2.5, 5 ma ọ bụ 10mg / kg arọ ahụ).A na-enye Prime-o-glucosylglycine intraperitoneal.Mgbe elekere 1 gachara, a na-enye ụmụ oke na LPS otu na LPS + prime-o-glucosylglycine otu 50 mg / L intranasal (200 mg / L) μ LLPs iji kpata nnukwu mmerụ ahụ nku ume.Enyere ụmụ oke njikwa ahụ 50% intranasal (na) na-enweghị LPS μ LPBS
[1]

Ntụaka:
[1].Zhou J, et al.Prim-O-glucosylcimifugin Attenuates Lipopolysaccharide na-ebute nzaghachi mkparị na RAW 264.7 Macrophages.Pharmacogn Mag.2017 Jul-Sep; 13 (51): 378-384 .
[2].Chen N, et al.Prime-O-glucosylcimifugin na-ebelata mmerụ ahụ nku ume nke lipopolysaccharide kpatara na ụmụ oke.Int Immunopharmacol.2013 Jun; 16 (2): 139-47 .